R
Revolution Medicines
On Target to Outsmart Cancer
About Revolution Medicines
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127, which are currently in clinical development.
Industry
Biotechnology Research
Headquarters
Redwood City, California
Company size
1001-5000
Founded
2014
What we do
RAS-addicted cancer therapiesTargeted oncologyDrug discovery and development
Interested in Revolution Medicines?
Join our talent pool to be considered for future opportunities.